288 related articles for article (PubMed ID: 31192313)
1. Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers.
Offin M; Guo R; Wu SL; Sabari J; Land JD; Ni A; Montecalvo J; Halpenny DF; Buie LW; Pak T; Liu D; Riely GJ; Hellmann MD; Benayed R; Arcila M; Kris MG; Rudin CM; Li BT; Ladanyi M; Rekhtman N; Drilon A
JCO Precis Oncol; 2019; 3():. PubMed ID: 31192313
[No Abstract] [Full Text] [Related]
2. Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.
Drilon A; Bergagnini I; Delasos L; Sabari J; Woo KM; Plodkowski A; Wang L; Hellmann MD; Joubert P; Sima CS; Smith R; Somwar R; Rekhtman N; Ladanyi M; Riely GJ; Kris MG
Ann Oncol; 2016 Jul; 27(7):1286-91. PubMed ID: 27056998
[TBL] [Abstract][Full Text] [Related]
3. Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers.
Drilon A; Lin JJ; Filleron T; Ni A; Milia J; Bergagnini I; Hatzoglou V; Velcheti V; Offin M; Li B; Carbone DP; Besse B; Mok T; Awad MM; Wolf J; Owen D; Camidge DR; Riely GJ; Peled N; Kris MG; Mazieres J; Gainor JF; Gautschi O
J Thorac Oncol; 2018 Oct; 13(10):1595-1601. PubMed ID: 30017832
[TBL] [Abstract][Full Text] [Related]
4. Frontline pembrolizumab for the treatment of RET-rearranged non-small cell lung cancer: A case report.
Baby S; Khalil F; Tanvetyanon T
Cancer Treat Res Commun; 2021; 28():100423. PubMed ID: 34166867
[TBL] [Abstract][Full Text] [Related]
5. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.
Gautschi O; Milia J; Filleron T; Wolf J; Carbone DP; Owen D; Camidge R; Narayanan V; Doebele RC; Besse B; Remon-Masip J; Janne PA; Awad MM; Peled N; Byoung CC; Karp DD; Van Den Heuvel M; Wakelee HA; Neal JW; Mok TSK; Yang JCH; Ou SI; Pall G; Froesch P; Zalcman G; Gandara DR; Riess JW; Velcheti V; Zeidler K; Diebold J; Früh M; Michels S; Monnet I; Popat S; Rosell R; Karachaliou N; Rothschild SI; Shih JY; Warth A; Muley T; Cabillic F; Mazières J; Drilon A
J Clin Oncol; 2017 May; 35(13):1403-1410. PubMed ID: 28447912
[TBL] [Abstract][Full Text] [Related]
6. Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET).
Takeuchi S; Yanagitani N; Seto T; Hattori Y; Ohashi K; Morise M; Matsumoto S; Yoh K; Goto K; Nishio M; Takahara S; Kawakami T; Imai Y; Yoshimura K; Tanimoto A; Nishiyama A; Murayama T; Yano S
Transl Lung Cancer Res; 2021 Jan; 10(1):314-325. PubMed ID: 33569315
[TBL] [Abstract][Full Text] [Related]
7. Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study.
Lu C; Dong XR; Zhao J; Zhang XC; Chen HJ; Zhou Q; Tu HY; Ai XH; Chen XF; An GL; Bai J; Shan JL; Wang YN; Yang SY; Liu X; Zhuang W; Wu HT; Zhu B; Xia XF; Chen RR; Gu DJ; Xu HM; Wu YL; Yang JJ
J Hematol Oncol; 2020 Apr; 13(1):37. PubMed ID: 32295619
[TBL] [Abstract][Full Text] [Related]
8. RET Fusion Lung Carcinoma: Response to Therapy and Clinical Features in a Case Series of 14 Patients.
Sarfaty M; Moore A; Neiman V; Dudnik E; Ilouze M; Gottfried M; Katznelson R; Nechushtan H; Sorotsky HG; Paz K; Katz A; Saute M; Wolner M; Moskovitz M; Miller V; Elvin J; Lipson D; Ali S; Gutman LS; Dvir A; Gordon N; Peled N
Clin Lung Cancer; 2017 Jul; 18(4):e223-e232. PubMed ID: 28082048
[TBL] [Abstract][Full Text] [Related]
9. Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung Cancer.
Lin JJ; Kennedy E; Sequist LV; Brastianos PK; Goodwin KE; Stevens S; Wanat AC; Stober LL; Digumarthy SR; Engelman JA; Shaw AT; Gainor JF
J Thorac Oncol; 2016 Nov; 11(11):2027-2032. PubMed ID: 27544060
[TBL] [Abstract][Full Text] [Related]
10. Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion.
Tsai TH; Wu SG; Hsieh MS; Yu CJ; Yang JC; Shih JY
Lung Cancer; 2015 May; 88(2):208-14. PubMed ID: 25773866
[TBL] [Abstract][Full Text] [Related]
11. From genotype to phenotype: Are there imaging characteristics associated with lung adenocarcinomas harboring RET and ROS1 rearrangements?
Plodkowski AJ; Drilon A; Halpenny DF; O'Driscoll D; Blair D; Litvak AM; Zheng J; Moskowitz CS; Ginsberg MS
Lung Cancer; 2015 Nov; 90(2):321-5. PubMed ID: 26424208
[TBL] [Abstract][Full Text] [Related]
12. Small-Cell Lung Cancer Transformation as a Mechanism of Resistance to Pralsetinib in RET-Rearranged Lung Adenocarcinoma: A Case Report.
Gazeu A; Aubert M; Pissaloux D; Lantuejoul S; Pérol M; Ikhlef N; Bouhamama A; Franceschi T; Swalduz A
Clin Lung Cancer; 2023 Jan; 24(1):72-75. PubMed ID: 36437214
[TBL] [Abstract][Full Text] [Related]
13. Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice.
Lee J; Ku BM; Shim JH; La Choi Y; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Jpn J Clin Oncol; 2020 May; 50(5):594-601. PubMed ID: 32083304
[TBL] [Abstract][Full Text] [Related]
14. Decade in review: a new era for RET-rearranged lung cancers.
Choudhury NJ; Drilon A
Transl Lung Cancer Res; 2020 Dec; 9(6):2571-2580. PubMed ID: 33489819
[TBL] [Abstract][Full Text] [Related]
15. Selpercatinib for lung and thyroid cancers with RET gene mutations or fusions.
Zheng H; Chen ZS; Li J
Drugs Today (Barc); 2021 Oct; 57(10):621-629. PubMed ID: 34713870
[TBL] [Abstract][Full Text] [Related]
16. Characterization of Computed Tomography Imaging of Rearranged During Transfection-rearranged Lung Cancer.
Saiki M; Kitazono S; Yoshizawa T; Dotsu Y; Ariyasu R; Koyama J; Sonoda T; Uchibori K; Nishikawa S; Yanagitani N; Horiike A; Ohyanagi F; Oikado K; Ninomiya H; Takeuchi K; Ishikawa Y; Nishio M
Clin Lung Cancer; 2018 Sep; 19(5):435-440.e1. PubMed ID: 29885946
[TBL] [Abstract][Full Text] [Related]
17. Precision oncology with selective RET inhibitor selpercatinib in
Gouda MA; Subbiah V
Ther Adv Med Oncol; 2023; 15():17588359231177015. PubMed ID: 37360768
[TBL] [Abstract][Full Text] [Related]
18. RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis.
Tsuta K; Kohno T; Yoshida A; Shimada Y; Asamura H; Furuta K; Kushima R
Br J Cancer; 2014 Mar; 110(6):1571-8. PubMed ID: 24504365
[TBL] [Abstract][Full Text] [Related]
19. Whole-exome sequencing explored mechanism of selpercatinib resistance in RET-rearranged lung adenocarcinoma transformation into small-cell lung cancer: a case report.
Peng Y; Zheng Z; Zewen W; Yanan L; Mingyan Z; Meili S
BMC Pulm Med; 2023 Dec; 23(1):492. PubMed ID: 38057798
[TBL] [Abstract][Full Text] [Related]
20. Outcomes With Local Therapy and Tyrosine Kinase Inhibition in Patients With
Hubbeling H; Choudhury N; Flynn J; Zhang Z; Falcon C; Rusch VW; Park BJ; Ziv E; Shaverdian N; Gelblum DY; Shepherd AF; Simone CB; Wu AJ; Gomez DR; Drilon A; Rimner A
JCO Precis Oncol; 2022 Oct; 6():e2200024. PubMed ID: 36201714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]